Ionis Pharmaceuticals, Inc. (IONS): Price and Financial Metrics


Ionis Pharmaceuticals, Inc. (IONS): $38.98

-1.34 (-3.32%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

IONS POWR Grades

  • Quality is the dimension where IONS ranks best; there it ranks ahead of 88.84% of US stocks.
  • IONS's strongest trending metric is Growth; it's been moving down over the last 178 days.
  • IONS's current lowest rank is in the Momentum metric (where it is better than 12.41% of US stocks).

IONS Stock Summary

  • With a price/earnings ratio of 780.01, IONIS PHARMACEUTICALS INC P/E ratio is greater than that of about 99.37% of stocks in our set with positive earnings.
  • The price/operating cash flow metric for IONIS PHARMACEUTICALS INC is higher than 89.55% of stocks in our set with a positive cash flow.
  • Of note is the ratio of IONIS PHARMACEUTICALS INC's sales and general administrative expense to its total operating expenses; merely 6.28% of US stocks have a lower such ratio.
  • Stocks with similar financial metrics, market capitalization, and price volatility to IONIS PHARMACEUTICALS INC are MRCY, ICCC, EBAY, CARS, and PINS.
  • Visit IONS's SEC page to see the company's official filings. To visit the company's web site, go to www.ionispharma.com.

IONS Valuation Summary

  • IONS's price/earnings ratio is 782.3; this is 3243.16% higher than that of the median Healthcare stock.
  • Over the past 243 months, IONS's price/earnings ratio has gone up 787.6.

Below are key valuation metrics over time for IONS.

Stock Date P/S P/B P/E EV/EBIT
IONS 2022-12-02 6.5 9.6 782.3 335.2
IONS 2022-12-01 6.5 9.6 780.0 334.3
IONS 2022-11-30 6.6 9.7 791.4 338.5
IONS 2022-11-29 6.3 9.3 752.1 324.1
IONS 2022-11-28 6.5 9.6 782.5 335.3
IONS 2022-11-25 6.7 9.9 806.4 344.0

IONS Growth Metrics

    The 5 year revenue growth rate now stands at 176.6%.
  • Its year over year price growth rate is now at -0.78%.
  • Its 4 year cash and equivalents growth rate is now at 474.12%.
Over the past 52 months, IONS's revenue has gone up $320,107,000.

The table below shows IONS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 875.483 129.512 7.321
2022-06-30 848.809 98.367 -28.153
2022-03-31 840.768 53.811 -3.893
2021-12-31 810.456 30.799 -28.597
2021-09-30 660.731 -74.911 -593.481
2021-06-30 687.717 -29.694 -541.959

IONS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • IONS has a Quality Grade of C, ranking ahead of 48.06% of graded US stocks.
  • IONS's asset turnover comes in at 0.277 -- ranking 161st of 682 Pharmaceutical Products stocks.
  • EDIT, MYMD, and VSTM are the stocks whose asset turnover ratios are most correlated with IONS.

The table below shows IONS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.277 0.982 -0.099
2021-06-30 0.269 0.983 -0.073
2021-03-31 0.262 0.983 -0.051
2020-12-31 0.250 0.984 -0.031
2020-09-30 0.298 0.990 0.050
2020-06-30 0.306 0.992 0.063

IONS Price Target

For more insight on analysts targets of IONS, see our IONS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $55.82 Average Broker Recommendation 1.82 (Hold)

IONS Stock Price Chart Interactive Chart >

Price chart for IONS

IONS Price/Volume Stats

Current price $38.98 52-week high $48.82
Prev. close $40.32 52-week low $26.41
Day low $38.78 Volume 1,436,071
Day high $40.43 Avg. volume 1,060,195
50-day MA $43.63 Dividend yield N/A
200-day MA $39.91 Market Cap 5.54B

Ionis Pharmaceuticals, Inc. (IONS) Company Bio


Ionis Pharmaceuticals, Inc., a RNA-targeted drug discovery and development company, focuses on developing drugs for patients with severe and rare diseases. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.


IONS Latest News Stream


Event/Time News Detail
Loading, please wait...

IONS Latest Social Stream


Loading social stream, please wait...

View Full IONS Social Stream

Latest IONS News From Around the Web

Below are the latest news stories about IONIS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate IONS as an investment opportunity.

Ionis (IONS) Inks Deal to Develop Precision Genetic Medicines

Ionis (IONS) inks collaboration deal with the gene editing company, Metagenomi, to expand the former's capabilities in delivering precision genetic medicines.

Yahoo | November 15, 2022

How rooting around in the dirt landed an East Bay startup an $80M deal

It is the second drug-target deal disclosed by the four-year-old UC Berkeley spinout in the past five months.

Yahoo | November 14, 2022

Ionis partners with Metagenomi to add gene editing to its broad technology platform

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Metagenomi today announced that the companies have entered a collaboration that will leverage Ionis' extensive expertise in RNA-targeted therapeutics and Metagenomi's versatile next-generation gene editing systems to pursue a mix of validated and novel genetic targets that have potential to expand therapeutic options for patients. The companies will jointly conduct research aimed initially at delivering investigational medicines for up to four genet

Yahoo | November 14, 2022

Ionis presents positive Phase 2 data from open label extension study of donidalorsen at 2022 ACAAI Annual Meeting

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today presented positive results from a Phase 2 open-label extension (OLE) study evaluating the safety and efficacy of its investigational antisense medicine, donidalorsen, in patients with hereditary angioedema (HAE), a rare and devastating inflammatory disease. Interim data after all patients completed 1 year of treatment in the study showed a sustained reduction in HAE attacks and no new safety signals following treatment with donidalorsen. Treatment

Yahoo | November 13, 2022

Should You Be Worried About Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) 1.2% Return On Equity?

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...

Yahoo | November 11, 2022

Read More 'IONS' Stories Here

IONS Price Returns

1-mo -6.19%
3-mo -6.41%
6-mo 11.37%
1-year 47.71%
3-year -39.67%
5-year -25.81%
YTD 28.10%
2021 -46.18%
2020 -6.41%
2019 11.75%
2018 7.48%
2017 5.16%

Continue Researching IONS

Want to see what other sources are saying about Ionis Pharmaceuticals Inc's financials and stock price? Try the links below:

Ionis Pharmaceuticals Inc (IONS) Stock Price | Nasdaq
Ionis Pharmaceuticals Inc (IONS) Stock Quote, History and News - Yahoo Finance
Ionis Pharmaceuticals Inc (IONS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7948 seconds.